Compare XTNT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | LUNG |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.7M | 72.2M |
| IPO Year | 2009 | 2020 |
| Metric | XTNT | LUNG |
|---|---|---|
| Price | $0.58 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.50 | ★ $5.38 |
| AVG Volume (30 Days) | 99.1K | ★ 680.2K |
| Earning Date | 03-06-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.03 | N/A |
| Revenue | $53,337,000.00 | ★ $90,497,000.00 |
| Revenue This Year | $15.08 | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | $19.34 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.34 | $1.31 |
| 52 Week High | $0.95 | $7.97 |
| Indicator | XTNT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 37.62 |
| Support Level | $0.55 | N/A |
| Resistance Level | $0.68 | $2.01 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 26.21 | 5.29 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.